Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
Michael Trang, David C. Griffith, Sujata M. Bhavnani, J. Loutit, Michael N. Dudley, Paul G. Ambrose, Christopher M. Rubino
Abstract
, and volume of the peripheral compartment were systematically different between phase 1 noninfected subjects and phase 3 infected patients. Visual predictive checks demonstrated minimal bias, supporting the robustness of the final models. These models were useful for generating individual PK exposures for pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy and Monte Carlo simulations to evaluate PK-PD target attainment.
Topics & Concepts
PharmacokineticsMedicineVolume of distributionNONMEMMeropenemRenal functionPopulationPharmacodynamicsClearanceCovariateUrinary systemAntibioticsPharmacologyInternal medicineUrologyBiologyMicrobiologyAntibiotic resistanceStatisticsMathematicsEnvironmental healthAntibiotics Pharmacokinetics and EfficacyAntibiotic Resistance in BacteriaPneumonia and Respiratory Infections